Cynvenio Releases Second-Generation ClearID Breast Cancer Blood Test
Higher Sensitivity Liquid Biopsy Test Brings New Precision and
Affordability to Cancer Care
WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–Cynvenio Biosystems, Inc. a leader in individualized cancer diagnostics,
has released its updated ClearID® Breast Cancer blood test.
ClearID leverages a custom-developed next-generation sequencing panel of
27 genes known to be altered in breast cancer to quickly and accurately
identify tumor genetic mutations that can be treated with targeted
therapies. The new ClearID test identifies circulating tumor cell burden
and detects emergent genetic alterations associated with resistance to
therapy, and has been optimized to monitor patients with advanced breast
cancer during initiation of therapy and at regular intervals following
treatment.
The ClearID test is based on Cynvenio’s unique LiquidBiopsy®
approach to tumor monitoring, which analyzes a combination of DNA from
circulating tumor cells (CTC), cell-free DNA (cfDNA), and germline DNA.
This multi-sourced DNA (MDA) analysis gives direct insight into the
progression of the primary tumor and the metastatic disease process
while increasing specificity by using germline DNA as a built-in
control. ClearID Breast Cancer is more comprehensive than first
generation cell-free DNA assays and is priced at a fraction of their
cost. Test results are summarized in a clear, actionable report
containing clinical interpretations of the identified biomarkers and
variants, their association with drugs, related clinical trials, and
experimental therapies to support treatment strategies.
“ClearID provides precise insights into disease progression on a
molecular level, enabling physicians to closely monitor changes in tumor
status and providing patients with peace of mind,” said Paul Song, M.D.,
Cynvenio’s Chief Medical Officer. “The ClearID Breast Cancer Test
provides clinicians with real-time, actionable information that will
transform cancer care from diagnosis and monitoring to choosing targeted
therapies and finding the clinical trials most appropriate for each
patient.”
ClearID Breast Cancer liquid biopsy can be used to complement
conventional tissue biopsy. Requiring only a standard blood draw,
ClearID is easier on the patient and can be easily repeated to monitor
changes in tumor status over time. ClearID is particularly useful when
there is difficulty obtaining tissue biopsy material, or when it is not
practical or advisable to do so for clinical reasons.
“We are committed to making ClearID affordable and accessible to all
patients,” commented André de Fusco, Cynvenio’s Chief Executive Officer.
“Today we are also announcing our new ClearBilling program that makes it
easy to file for insurance reimbursement. ClearBilling supports our goal
of providing responsive and accurate testing that can enable doctors to
truly personalize treatment choices for their patients and their
families.”
About Cynvenio Biosystems, Inc.
Cynvenio Biosystems, Inc. is an emerging leader in the development of
more affordable and clinically actionable precision medicine strategies
for cancer patients. Cynvenio’s liquid biopsy blood tests accurately
target known DNA & RNA mutations in cancer-related genes to
revolutionize personalized treatment decision making and clinical trial
selection. Among the company’s breakthroughs are an expanding line of
ClearID® tests engineered for greatly improved cancer
detection and monitoring via a patient-friendly blood draw, and
proprietary LiquidBiopsy® automated platform technology which
is distributable and makes real-time molecular tumor characterization
from whole blood a practical reality for any lab. Cynvenio is based in
Westlake Village, California. For more information, please visit or more
information, please www.cynvenio.com
Contacts
Bioscribe, Inc.
Nicole Litchfield, 415-793-6468
nicole@bioscribe.com
